Resistance to therapeutic treatment and metastatic progression jointly determine a fatal
outcome of cancer. Cancer metastasis and therapeutic resistance are traditionally studied as …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Rare circulating tumor cells (CTCs) present in the bloodstream of patients with cancer
provide a potentially accessible source for detection, characterization, and monitoring of …

Early spread of tumor cells is usually undetected by current imaging technologies. In
patients with cancer and no signs of overt metastases sensitive methods have been …

Purpose Cabozantinib is an inhibitor of kinases, including MET and vascular endothelial
growth factor receptors, and has shown activity in men with previously treated metastatic …

Rare circulating tumor cells (CTCs) are present in the blood of patients with metastatic
epithelial cancers but have been difficult to measure routinely. We report a quantitative …

Background Androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs)
from patients with metastatic castration-resistant prostate cancer (mCRPC) was recently …

Background Intermediate or surrogate endpoints for survival can shorten time lines for drug
approval. We aimed to assess circulating tumour cell (CTC) count as a prognostic factor for …

Purpose It has been postulated that castration-resistant prostate cancer (CRPC) commonly
remains hormone dependent. Abiraterone acetate is a potent, selective, and orally available …

Hormone-driven expression of the ERG oncogene after fusion with TMPRSS2 occurs in 30%
to 70% of therapy-naive prostate cancers. Its relevance in castration-resistant prostate …